Lei Sun

Dr. Sun has over 20 years of experiences in pharmaceutical development of biologics focused on process development, CMC, and manufacturing operations. Prior to Joining Connect, Dr. Sun served as Chief Technology Office and Vice president of Manufacturing at Autebio, where he established the first process development and manufacturing platform in China using single use bioreactors. His CMC team supported clients to successfully develop biologic products through IND filing and clinical trials in China as well as in US. Prior to serving at Autobio, Dr. Sun was a leading member of the teams for the development and successful marketing of multiple biologic drugs at Hughes Institute, UCB Pharma, Shire Pharmaceuticals and DSM/Crucell JV, where he played a leading role in the CMC development of several biologics products including antibody ADC, immune modulators, and orphan drugs. Dr. Sun was a founding member of DSM/Crucell JV in Boston where he established innovative biologic process platform and, in 2006, made record yield in biologics manufacturing. Dr. Sun has more than 20 publications in peer-reviewed journals and was an inventor of multiple patents in biologics and process development. Dr. Sun obtained his Ph.D. degree in molecular biology and biochemistry from the University of Minnesota and received his postdoctoral training in molecular immunology at Harvard Medical School.